Telomerase activity in benign and malignant epithelial ovarian tumors

Journal of the National Cancer Institute

Volumn 89, Issue 6, 1997, Pages 437-441

  Wan, Minghong ^a,c   Li, Wei Zhi ^a   Duggan, Bridgette D ^b   Felix, Juan C ^a   Zhao, Yanle ^a   Dubeau, Louis ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE;

ARTICLE; BENIGN TUMOR; CELL DIVISION; CELL IMMORTALIZATION; DNA REPLICATION; ENZYME ACTIVITY; EPITHELIUM CELL; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; OVARY TUMOR; TANDEM REPEAT; TELOMERE;

EID: 0030962458     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.6.437     Document Type: Article

References (21)

1. Scully RE. Ovarian tumors. A review. Am J Pathol 1977;87:686-720.
2. Cheng PC, Schmutte C, Cofer KF, Felix JC, Yu MC, Dubeau L. Alterations in DNA methylation are early, but not initial events in ovarian tumorigenesis. Br J Cancer 1997;75:396-402.
3. Bell DA. Ovarian surface epithelial-stromal tumors. Hum Pathol 1991;22:750-62.
4. Kurman RJ, Trimble CL. The behavior of serous tumors of low malignant potential: are they ever malignant? Int J Gynecol Pathol 1993;12:120-7.
5. Chong L, van Steensel B, Broccoli D, Erdjument-Bromage H, Hanish J, Tempst P, et al. A human telomeric protein. Science 1995;270:1663-7.
6. Zakian VA. Telomeres: beginning to understand the end. Science 1995;270:1601-7.
7. Rhyu MS. Telomeres, telomerase, and immortality. J Natl Cancer Inst 1995;87:884-94.
8. Harley CB, Futcher B, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990;345:458-60.
9. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-5.
10. Chadeneau C, Hay K, Hirte HW, Gallinger S, Bacchetti S. Telomerase activity associated with acquisition of malignancy in human colorectal cancer. Cancer Res 1995;55:2533-6.
11. Counter CM, Hirte HW, Bacchetti S, Harley CB. Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci U S A 1994;91:2900-4.
12. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, et al. The RNA component of human telomerase. Science 1995;269:1236-41.
13. Cheng PC, Gosewehr JA, Kim TM, Velicescu M, Wan M, Zheng J, et al. Potential role of the inactivated X chromosome in ovarian epithelial tumor development. J Natl Cancer Inst 1996;88:510-8.
14. Seidman JD, Kurman RJ. Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol 1996;20:1331-45.
15. Stamps AC, Gusterson BA, O'Hare MJ. Are tumours immortal? Eur J Cancer 1992;28A:1495-500.
16. Blasco MA, Rizen M, Greider CW, Hanahan D. Differential regulation of telomerase activity and telomerase RNA during multi-stage tumorigenesis. Nat Genet 1996;12:200-4.
17. Klingelhutz AJ, Foster SA, McDougall JK. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 1996;380:79-82.
18. Morin GB. Is telomerase a universal cancer target? J Natl Cancer Inst 1995;87:859-61.
19. Parkinson EK. Do telomerase antagonists represent a novel anti-cancer strategy? Br J Cancer 1996;73:1-4.
20. Gupta J, Han LP, Wang P, Gallie BL, Bacchetti S. Development of retinoblastoma in the absence of telomerase activity. J Natl Cancer Inst 1996;88:1152-7.
21. Vuento MH, Pirhonen JP, Makinen JI, Laippala PJ, Gronroos M, Salmi TA. Evaluation of ovarian findings in asymptomatic postmenopausal women with color Doppler ultrasound. Cancer 1995;76:1214-8.